Germany’s Expert Committee for Prescription was not convinced of the value of making Perrigo’s progestogen-only contraceptive pill available OTC, according to the recently-published minutes of its 23 January meeting.
Why Did Germany’s Switch Committee Reject Perrigo’s OTC Daily Contraceptive Proposal?
Skepticism about the need for widening access to the progestogen-only contraceptive pill, fears of associated thrombosis risk with use and the potential cost barriers were among the many reasons for the unanimous rejection of Perrigo's Rx-to-OTC switch application for desogestrel (75μg) for oral use.